§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇦🇪United Arab Emirates 3 of 4 pathway fees confirmed	🇪🇺European Union Fees verified 12 September 2026
Authority & dossier
Fee confirmation	3 of 4 pathway fees confirmed	Fees verified 12 September 2026
Regulatory authority	MoHAP	EMA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA, EMA (centralised), MHRA, Health Canada +3	Not stated
Lead pathway (timeline & fees), Federal Drug Registration (Standard) · Centralised Procedure
Pathway name	Federal Drug Registration (Standard)	Centralised Procedure
Approval timeline	180-365 days	210-277 days
Headline fee and pathway	AED 7,100, Federal Drug Registration (Standard)	EUR 865,200, Centralised Procedureconditional on other
Recurring charges	AED 3,500 every 5 years, per marketing authorisation	EUR 232,400 a year, per marketing authorisation, other applications
Local representative	Required	Required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	A UAE-resident Registered Pharmacist must be designated as Responsible Pharmacist for the Drug Store Licence. A separate Pharmacovigilance Officer is required and must report to MoHAP Pharmacovigilance.	Qualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Priority Review, Orphan Drug Pathway, Pandemic Emergency Use Authorisation +1	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Post-approval variations broadly aligned with EU Type IA/IB/II framework. Major variations require MoHAP approval; Minor follow tacit-approval procedures.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	Marketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.	Initial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	MoHAP Pharmacovigilance Department; PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre. UAE is a WHO-UMC member.	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-90 days	60-106 days
GCP standard	ICH-GCP	ICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	Yes
HTA required	No	Yes
HTA body	Emerging, DoH and DHA developing emirate-level HTA; no federal HTA agency yet	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

United Arab Emirates3 of 4 pathway fees confirmed
European UnionFees verified 12 September 2026

Regulatory authority

United Arab EmiratesMoHAP
European UnionEMA

English submissions

United Arab EmiratesYes
European UnionYes

CTD accepted

United Arab EmiratesYes
European UnionYes

eCTD accepted

United Arab EmiratesYes
European UnionYes

Reliance pathway

United Arab EmiratesAvailable
European UnionAvailable

Reference agencies

United Arab EmiratesFDA, EMA (centralised), MHRA, Health Canada +3
European UnionNot stated

Lead pathway (timeline & fees), Federal Drug Registration (Standard) · Centralised Procedure

Pathway name

United Arab EmiratesFederal Drug Registration (Standard)
European UnionCentralised Procedure

Approval timeline

United Arab Emirates180-365 days
European Union210-277 days

Headline fee and pathway

United Arab EmiratesAED 7,100, Federal Drug Registration (Standard)
European UnionEUR 865,200, Centralised Procedureconditional on other

Recurring charges

United Arab EmiratesAED 3,500 every 5 years, per marketing authorisation
European UnionEUR 232,400 a year, per marketing authorisation, other applications

Local representative

United Arab EmiratesRequired
European UnionRequired

Local manufacturing

United Arab EmiratesNot required
European UnionNot required

GMP inspection

United Arab EmiratesRequired
European UnionRequired

MAH & local presence

Local entity required

United Arab EmiratesYes
European UnionYes

Local responsible person

United Arab EmiratesYes
European UnionYes

RP role

United Arab EmiratesA UAE-resident Registered Pharmacist must be designated as Responsible Pharmacist for the Drug Store Licence. A separate Pharmacovigilance Officer is required and must report to MoHAP Pharmacovigilance.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

United Arab Emirates4 designations
European Union6 designations

Examples

United Arab EmiratesPriority Review, Orphan Drug Pathway, Pandemic Emergency Use Authorisation +1
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

United Arab EmiratesPost-approval variations broadly aligned with EU Type IA/IB/II framework. Major variations require MoHAP approval; Minor follow tacit-approval procedures.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

United Arab EmiratesMarketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.
European UnionInitial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

United Arab EmiratesMoHAP Pharmacovigilance Department; PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre. UAE is a WHO-UMC member.
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

United Arab EmiratesAvailable
European UnionAvailable

Compassionate Use

United Arab EmiratesAvailable
European UnionAvailable

Emergency Import

United Arab EmiratesAvailable
European UnionAvailable

Parallel Import

United Arab EmiratesNot permitted
European UnionPermitted

Clinical trials

CTA approval

United Arab EmiratesRequired
European UnionRequired

Ethics approval

United Arab EmiratesYes
European UnionYes

CTA timeline

United Arab Emirates60-90 days
European Union60-106 days

GCP standard

United Arab EmiratesICH-GCP
European UnionICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

United Arab EmiratesRegulated
European UnionRegulated

Reference pricing

United Arab EmiratesYes
European UnionYes

HTA required

United Arab EmiratesNo
European UnionYes

HTA body

United Arab EmiratesEmerging, DoH and DHA developing emirate-level HTA; no federal HTA agency yet
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)